RecruitingPhase 1NCT07600762

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nascertib Moves Through the Body In Healthy Adult Japanese Participants

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Nascertib in Healthy Adult Japanese Subjects

Sponsor

AbbVie

Enrollment

12 participants

Start Date

Apr 21, 2026

Study Type

INTERVENTIONAL

Conditions

A Study to Assess Adverse Events, Tolerability and How a Single Oral Dose of Nascertib Moves Through the Body In Healthy Adult Japanese Participants

Min Age: 18 YearsMax Age: 65 Years

Healthy Japanese male or female; 18 to 65 years of age at the time of screening.
Japanese participant must be first-or second-generation Japanese of full Japanese parentage. First-generation participants will have been born in Japan to two parents and four grandparents also born in Japan of full Japanese descent. Second-generation participants born outside of Japan must have two parents and four grandparents born in Japan of full Japanese descent.
BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenth decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.

History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
History of any clinically significant sensitivity or allergy to any medication or food.
History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption \[e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.\].

Interested in this trial?

Get notified about updates and connect with the research team.